Navigation Links
Bionovo Announces Decision to Explore Strategic Options and to Delay Announcement of Financial Results for 2011
Date:2/21/2012

EMERYVILLE, Calif., Feb. 21, 2012 /PRNewswire/ -- Bionovo, Inc. (OTC Link Platform:  BNVI.PK), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced its decision to explore strategic options.  As a result of this decision, the Company has decided to delay the announcement of its financial results for the year ended December 31, 2011, previously planned for today, to a later date.  The Company will provide an update for the release of its 2011 financial results within the next two weeks.

(Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO)

"We believe Menerba, our drug for the treatment of menopausal hot flashes currently in a Phase 3 trial, is a very valuable asset and we are focusing all of our efforts to complete that clinical trial," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "We are pursuing financial options to fund completion of the pivotal trial, but the outcome of those efforts cannot be assured.  We have therefore decided to explore in parallel, strategic options that may provide more value to our shareholders and ensure the continued development of Bionovo's products."

The Company has engaged Cowen and Company to assist Bionovo to explore its strategic options.

The Company will need to obtain substantial amounts of cash to achieve its objectives of internally developing drugs.  The Company does not currently have adequate internal liquidity to meet its cash needs in the near term including completion of the ongoing Phase 3 trial for Menerba.  If sufficient additional funds are not received in the near term, the Company may not be able to execute its business plan and may need to significantly curtail or cease operations.

About Bionovo, Inc.'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo to Host Conference Call to Discuss 2011 Highlights and Year-End Financial Results
2. Bionovo Announces Third Quarter 2011 Highlights and Financial Results
3. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
4. Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
5. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
6. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
7. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
8. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
9. Bionovo to Announce First Quarter Financial Results on Wednesday, May 11, 2011
10. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
11. Bionovo Announces 2010 Highlights and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014  Decision Resources Group finds that ... factor (VEGF) agent for wet AMD, is equally likely ... as Genentech,s Lucentis, which is the standard of care ... organization (MCO) directors do not identify a clear clinical ... likely than Lucentis to be listed on tier 1 ...
(Date:9/18/2014)... -- Zacks.com announces the list of stocks featured in the ... discuss the latest news and events impacting stocks and ... include the Avanir Pharmaceuticals (Nasdaq: AVNR - Free Report ... ), Orexigen (Nasdaq: OREX - Free Report ), ... Gilead (Nasdaq: GILD - Free Report ). ...
(Date:9/18/2014)... , Sept. 18, 2014 Veterinary biologic ... Dr. Ashraf Hanna , M.D., Ph.D., and Dr. ... of Directors. Dr. Hanna is the Vice President of ... Financial Officer for the Genentech Foundation, while Dr. McCracken ... of Business Development and Licensing for Roche Pharma. ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3
(Date:9/18/2014)... Amy Norton HealthDay Reporter ... single dose of a common antidepressant can quickly alter the ... The findings, reported online Sept. 18 in ... brain,s response to widely prescribed antidepressants. Experts said the hope ... depression are likely to benefit from a drug -- and ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... breeding grounds for microbes -- don,t worry, it,s a ... years, not all microbes are bad. Many active enzymes ... beneficial to humans as an important part of our ... , Candida albicans , an opportunistic yeast pathogen ... doesn,t damage our healthy personal ecosystem. However, when our ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... September 18, 2014 As testosterone ... in U.S. courts, Bernstein Liebhard LLP notes that ... U.S. Food & Drug Administration (FDA) subject prescription ... implemented, could greatly reduce their use. The joint ... Drug Advisory Committee, and the Drug Safety and ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4
... -- A 2005 voluntary federal ban on the use of ... on all commercial shipping of such purchases within the United ... sell cigarettes, new research reveals. The ban was the ... private shippers, such as UPS and FedEx, made primarily to ...
... Reporter , FRIDAY, Feb. 25 (HealthDay News) -- Medical ... unique ways to solve challenging problems. But scientists can ... diseases, particularly when those methods involve animals or insects. ... team, which is studying fruit flies to help determine ...
... a rare disease and recurrent botulism even more rare. ... drug users has been on the rise and makes ... A new study published in Clinical Infectious ... examines this problem. From 1993 through 2006, 17 ...
... (HealthDay News) -- A fresh look at 19th century Mormon marriage ... offspring any one wife produced. "Although it,s great in terms ... that for every new woman added to a male,s household, the ... study author and evolutionary biologist Michael Wade, from Indiana University in ...
... HealthDay Reporter , THURSDAY, Feb. 24 (HealthDay News) ... to warn of impending dangers to human health if ... They believe the federal government, specifically the Environmental Protection ... emissions, however. "The science is unequivocal that global ...
... the 3rd International Conference on innovative approaches in Head ... colleagues at hospitals and institutes in Denmark presented results ... 7 study. The study, conducted across the country, investigated ... radiotherapy treatment for a head & neck cancer. "We ...
Cached Medicine News:Health News:Study Finds Drop in Online Sales of Cigarettes 2Health News:Seeking Alzheimer's Answers Among Fruit Flies 2Health News:Seeking Alzheimer's Answers Among Fruit Flies 3Health News:19th Century Polygamy Meant Fewer Kids Per Wife, Data Shows 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 3Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 4Health News:New way to identify patients at risk of dysphagia after head and neck cancer treatment 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: